Morikawa Teppei, Kuchiba Aya, Yamauchi Mai, Meyerhardt Jeffrey A, Shima Kaori, Nosho Katsuhiko, Chan Andrew T, Giovannucci Edward, Fuchs Charles S, Ogino Shuji
Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, 450 Brookline Ave, Boston, MA 02215, USA.
JAMA. 2011 Apr 27;305(16):1685-94. doi: 10.1001/jama.2011.513.
Alterations of the WNT signaling pathway and cadherin-associated protein β 1 (CTNNB1 or β-catenin) have been implicated in colorectal carcinogenesis and metabolic diseases.
To test the hypothesis that CTNNB1 activation in colorectal cancer modifies prognostic associations of body mass index (BMI) and level of postdiagnosis physical activity.
DESIGN, SETTING, AND PATIENTS: Two US prospective cohort studies (Nurses' Health Study and the Health Professionals Follow-up Study) were used to evaluate CTNNB1 localization by immunohistochemistry in 955 patients with stage I, II, III, or IV colon and rectal cancer from 1980 through 2004. A Cox proportional hazards model was used to compute the hazard ratio (HR) for mortality, adjusting for clinical and tumor features, including microsatellite instability, CpG island methylator phenotype, level of long interspersed nucleotide element 1 methylation, mutations in KRAS, BRAF, or PIK3CA, and tumor protein p53.
Colorectal cancer-specific mortality and overall mortality through June 30, 2009.
In obese patients (BMI ≥30), positive status for nuclear CTNNB1 was associated with significantly better colorectal cancer-specific survival (adjusted HR, 0.24 [95% confidence interval {CI}, 0.12-0.49], P <.001 for interaction; 5-year survival: 0.85 for patients with positive nuclear CTNNB1 status vs 0.78 for those with negative status) and overall survival (adjusted HR, 0.56 [95% CI, 0.35-0.90], P = .03 for interaction; 5-year survival: 0.77 for patients with positive nuclear CTNNB1 status vs 0.74 for those with negative status), while CTNNB1 status was not associated with prognosis among nonobese patients (BMI <30). Among patients with negative status for nuclear CTNNB1 and cancer in stages I, II, or III, postdiagnosis physical activity was associated with better colorectal cancer-specific survival (adjusted HR, 0.33 [95% CI, 0.13-0.81], P = .05 for interaction; 5-year survival: 0.97 for ≥18 vs 0.89 for <18 metabolic equivalent task hours/week), while postdiagnosis physical activity was not associated with colorectal cancer-specific survival among patients with positive status for nuclear CTNNB1 (adjusted HR, 1.07 [95% CI, 0.50-2.30]).
Among obese patients only, activation of CTNNB1 was associated with better colorectal cancer-specific survival and overall survival. Postdiagnosis physical activity was associated with better colorectal cancer-specific survival only among patients with negative status for nuclear CTNNB1. These molecular pathological epidemiology findings suggest that the effects of alterations in the WNT-CTNNB1 pathway on outcome are modified by BMI and physical activity.
WNT信号通路和钙黏蛋白相关蛋白β1(CTNNB1或β-连环蛋白)的改变与结直肠癌发生及代谢性疾病有关。
检验结直肠癌中CTNNB1激活改变体重指数(BMI)和诊断后体力活动水平的预后关联这一假设。
设计、地点和患者:两项美国前瞻性队列研究(护士健康研究和卫生专业人员随访研究)用于通过免疫组织化学评估1980年至2004年期间955例I、II、III或IV期结肠癌和直肠癌患者的CTNNB1定位。采用Cox比例风险模型计算死亡率的风险比(HR),并对临床和肿瘤特征进行调整,包括微卫星不稳定性、CpG岛甲基化表型、长散在核苷酸元件1甲基化水平、KRAS、BRAF或PIK3CA突变以及肿瘤蛋白p53。
至2009年6月30日的结直肠癌特异性死亡率和总死亡率。
在肥胖患者(BMI≥30)中,核CTNNB1阳性状态与显著更好的结直肠癌特异性生存率(调整后HR,0.24[95%置信区间{CI},0.12 - 0.49],交互作用P<.001;5年生存率:核CTNNB1阳性状态患者为0.85,阴性状态患者为0.78)和总生存率(调整后HR,0.56[95%CI,0.35 - 0.90],交互作用P = .03;5年生存率:核CTNNB1阳性状态患者为0.77,阴性状态患者为0.74)相关,而在非肥胖患者(BMI<30)中,CTNNB1状态与预后无关。在核CTNNB1阴性且处于I、II或III期癌症的患者中,诊断后体力活动与更好的结直肠癌特异性生存率相关(调整后HR,0.33[95%CI,0.13 - 0.81],交互作用P = .05;5年生存率:每周代谢当量任务小时≥18者为0.97,<18者为0.89),而在核CTNNB1阳性状态患者中,诊断后体力活动与结直肠癌特异性生存率无关(调整后HR,1.07[95%CI,0.50 - 2.30])。
仅在肥胖患者中,CTNNB1激活与更好的结直肠癌特异性生存率和总生存率相关。诊断后体力活动仅在核CTNNB1阴性状态患者中与更好的结直肠癌特异性生存率相关。这些分子病理流行病学研究结果表明,WNT - CTNNB1通路改变对结局的影响受BMI和体力活动的影响。